HRS4R
Vull donar

PILAR BARRETINA GINESTA

Firma
PILAR BARRETINA-GINESTA
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Publicacions

Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

CLINICAL CANCER RESEARCH, 2024, 30, 176-186 dx.doi.org/10.1158/1078-0432.CCR-23-0771
Redondo A, Barretina P, Pérez-Fidalgo A, Rubio MJ, González-Martín A

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 dx.doi.org/10.3802/jgo.2023.34.e57
Fernández-Serra A, López-Reig R, Márquez R, Gallego A, de Sande LM, Yubero A, Pérez-Segura C, Ramchandani-Vaswani A, Barretina-Ginesta MP, Mendizábal E, Esteban C, Gálvez F, Sánchez-Heras AB, Guerra-Alía EM, Gaba L, Quindós M, Palacio I, Alarcón J, Oaknin A, Aliaga J, Ramírez-Calvo M, García-Casado Z, Romero I, López-Guerrero JA

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study.

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15113030
Plaja A, Teruel I, Ochoa-de-Olza M, Cucurull M, Arroyo ÁJ, Pardo B, Ortiz I, Gil-Martin M, Piulats JM, Pla H, Fina C, Carbó A, Barretina-Ginesta MP, Martínez-Román S, Carballas E, González A, Esteve A, Romeo M

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 dx.doi.org/10.3390/ijms241411420
Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, Torres-Esquius S, Balmaña J, Lázaro C, Brunet JM, Barretina-Ginesta MP

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 26, 1033-1037 dx.doi.org/10.1007/s12094-023-03312-4
Carbó-Bagué A, Cerón-Nasarre L, Valls-Masot L, Melendez-Munoz C, Bujons-Buscarons E, Liñan-Planas R, Barretina-Ginesta MP

Esophageal Infiltration by High-Grade Serous Ovarian Carcinoma: A Very Rare Case Report.

Case Reports in Oncology, 2023, 16, 1436-1442 dx.doi.org/10.1159/000534702
Woopen H, Keller M, Zocholl D, Mittelstadt S, Barretina-Ginesta MP, Heinzelmann-Schwarz V, Lafleur J, Kocián R, Baum J, Krabisch P, Achimas-Cadariu P, Vardar MA, Vergote I, Nasser S, Link T, Gil-Martin M, Zwimpfer TA, Leitner K, Jedryka M, Boxler T, Braicu EI, Sehouli J

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15225428
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A, INOVATYON study group

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

BRITISH JOURNAL OF CANCER, 2023, 128, 1503-1513 dx.doi.org/10.1038/s41416-022-02108-7
Barretina-Ginesta MP, Quindós M, Alarcón JD, Esteban C, Gaba L, Gómez C, Fidalgo JAP, Romero I, Santaballa A, Rubio-Pérez MJ

SEOM-GEICO clinical guidelines on endometrial cancer (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 625-634 dx.doi.org/10.1007/s12094-022-02799-7
Romeo M, Gil-Martín M, Gaba L, Teruel I, Taus Á, Fina C, Masvidal M, Murata P, Fernández-Plana J, Martínez A, Pérez C, García Y, Rodriguez V, Cros S, Parera M, Zanui M, Catot S, Pardo B, Plaja A, Esteve A, Barretina-Ginesta MP

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14184414

Formulari de contacte

Coneix l’IDIBGI!

menu